Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficiency of Allogeneic Adoptive Immune Therapy for Advanced AIDS Patients

NCT04098770 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT04098770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04098770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficiency of Allogeneic Adoptive Immune Therapy for Advanced AIDS Patients
Lead sponsor
Beijing 302 Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 11, 2019
Completion date
December 30, 2024
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aids patients